352 (PB132) - Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

التفاصيل البيبلوغرافية
العنوان:	352 (PB132) - Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study
المؤلفون:	Saggu, G., Stroopinsky, D., Dudek, A.Z., Olszanski, A.J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R.J., Berger, A., Sachsenmeier, K., Kasar, S.
المصدر:	In European Journal of Cancer October 2022 174 Supplement 1:S125-S126
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	09598049
DOI:	10.1016/S0959-8049(22)01134-0